ClinicalTrials.gg
CompletedNCT02493543Updated Oct 21, 2026

Autoantibodies on Spinal Cord Injury

An observational study in Spinal Cord Injuries, sponsored by Hospital Nacional de Parapléjicos de Toledo. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Hospital Nacional de Parapléjicos de Toledo · Observational

Updated Oct 21, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
110
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Spinal Cord Injuries with a site in Germany — 3 open to participants now, 6 under way, none of them phase 3. Spinal Cord Injuries · Germany.

Started
2014
with 2 others
Observational
8 of 22
1 open now
Registered
9th of 22
by date
Lead sponsor
1 of 22
Hospital Nacional de Parapléjicos de Toledo

Among the 22 studies in Spinal Cord Injuries with a site in Germany, this one is one of 3 that started in 2014, is one of 8 observational ones, and was the 9th registered.

Spinal Cord Injuries

2,028 studies on the registry are indexed under Spinal Cord Injuries; 540 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

3 of the 22 studies in Spinal Cord Injuries with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 376 Spinal Cord Injuries studies recruiting now, 167 (44%) set no upper age limit and 158 (42%) stop at 75 or younger; 41 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Spinal Cord Injuries with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to determine the autoantibody profiles after spinal cord injury and their role in spontaneous functional recovery.

Read the detailed description

Most patients experience variable degrees of functional recovery after spinal cord injury (SCI), predominantly in the first months after lesion. In SCI animal models, autoantibodies are pathogenic and their titers rise up at the time when spontaneous recovery stops. The aim of this study is to determine the autoantibody profiles after SCI and to infer their relation with functional recovery. To achieve this, autoantibody profiles, biochemical, hematological and immune-related parameters (cytokines, chemokines and growth factors) will be determined from a serum blood sample and functional recovery will be evaluated accordingly to standardized scales.

03

Conditions studied

  • Spinal Cord Injuries

Keywords

  • autoantibodies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with acute spinal cord injury admitted to the Spanish National Hospital for Paraplegics

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Traumatic or non-progressive vascular SCI
  • Less than 45 days after lesion
  • Any neurological level
  • Complete and incomplete lesions
  • If patient has been treated with , it should have passed at least 7 days from the end of the treatment

Exclusion criteria

Exclusion Criteria:

  • Cauda equina syndrome
  • disorder
  • Tumor (even if benign)
  • Neurodegenerative disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
110 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Spinal cord injury

    Patients (n=90) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed twice: after recruitment and 3 months later.

    Other: Blood collection

  • Controls

    Control subjects (n=20) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed only once.

    Other: Blood collection

Interventions

  • OtherBlood collection

    Blood collection from the subject's arm

06

What researchers measure

Primary outcomes

  1. Changes in ASIA scores

    Time frame: 4 months

Secondary outcomes

  1. Change in neurological level of injury

    Time frame: 4 months

  2. Change in ASIA impairment scale (AIS)

    Time frame: 4 months

Other outcomes

  1. Spinal cord independence measure (SCIM)

    Time frame: Until discharge from the hospital (6-12 months)

07

Study locations

2 sites
  • Berufsgenossenschaftliche Unfallklinik Murnau
    Murnau am Staffelsee, Germany
  • Hospital Nacional de Parapléjicos, SESCAM
    Toledo, Spain
08

References and documents

Publications

  • Leister I, Altendorfer B, Maier D, Mach O, Wutte C, Grillhosl A, Arevalo-Martin A, Garcia-Ovejero D, Aigner L, Grassner L. Trajectory of Serum Levels of Glial Fibrillary Acidic Protein Within Four Weeks Post-Injury Is Related to Neurological Recovery During the Transition from Acute to Chronic Spinal Cord Injury. J Neurotrauma. 2023 May;40(9-10):999-1006. doi: 10.1089/neu.2022.0326. Epub 2022 Dec 9. PubMed 36200629 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Dec 2020, 74 months.

Of 124 non-industry observational studies under Spinal Cord Injuries, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 74. This study's 74 months is above that.

Counting every sponsor, half of 135 studies reached it within 39 months; a quarter within 16 and three quarters within 82.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Apr 2018 → Dec 2020 and completion Apr 2018 → Dec 2020.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2015
First posted
Jul 9, 2015
StartActual
Oct 17, 2014
Primary completionActual
Dec 31, 2020was Apr 2018
CompletionActual
Dec 31, 2020was Apr 2018
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 21, 2026
Sites
1 site added, 1 site removed
Show site
  • Berufsgenossenschaftliche Unfallklinik Murnau · Murnau am Staffelsee, Germany
Show 1 removed
  • Berufsgenossenschaftliche Unfallklinik Murnau · Murnau Am Staffelsee, Germany
Oct 21, 2026
Primary completion
Apr 2018→Dec 31, 2020 (actual)
Oct 21, 2026
Study completion
Apr 2018→Dec 31, 2020 (actual)
Oct 21, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 36200629 ↗
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Status unknown→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 36200629 ↗
    1 site added, 1 site removed
    Show site
    • Berufsgenossenschaftliche Unfallklinik Murnau · Murnau am Staffelsee, Germany
    Show 1 removed
    • Berufsgenossenschaftliche Unfallklinik Murnau · Murnau Am Staffelsee, Germany
    Primary completion Apr 2018→Dec 31, 2020 (now actual)
    Study completion Apr 2018→Dec 31, 2020 (now actual)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02493543
Lead sponsor
Hospital Nacional de Parapléjicos de Toledo
Collaborators
Fundación Mutua Madrileña
Responsible party
Dr. Angel Arevalo Martin (Ph.D., Hospital Nacional de Parapléjicos de Toledo) — Principal investigator
First posted
Jul 9, 2015
Start date
Oct 17, 2014
Primary completion
Dec 31, 2020
Completion
Dec 31, 2020
Last update
Oct 21, 2026

Study contacts

Angel Arevalo-Martin, PhD
principal investigator · Hospital Nacional de Parapléjicos, SESCAM

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion